Avita Medical Ltd Expected to Dominate Market for Burns and Scalds Treatment, Says Zacks Analyst via Interview With The Life Sciences Report
(firmenpresse) - SAN FRANCISCO, CA -- (Marketwired) -- 08/05/13 -- Jason Napodano, Senior Biotechnology Analyst at Zacks Investment Research, stated in an interview with George Mack of , ". (ASX: AVH) (OTCQX: AVMXY) has a regenerative medicine device product called ReCell® Spray-On Skin® (autologous cell suspension), a treatment for severe skin defects, burns, scalds, scars, vitiligo (discoloration of the skin when melanin is lost), acne scarring and what I call the holy grail of indications, chronic wounds. I like this product because it makes sense for burns and scalds, especially in children. It's a difficult story to communicate -- the pictures at the company's website are worth a thousand words. Avita's ReCell product is fantastic because all that is needed to generate the suspension is skin from a donor site about the size of a postage stamp, instead of a huge harvest that creates another large wound, and two painful sites that need to heal. With ReCell, a skin biopsy is put in the ReCell kit, which separates and isolates the patient's skin cells through an easy-to-follow, six-step process. The cells can then be sprayed onto the wound and a new layer of healthy skin grows. It's approved in Europe... in the U.S., ReCell is essentially in phase 3, and we'll get data from that trial next year. Then Avita will file for approval, and ReCell should be on the U.S. market in 2015. From a burns and scalds standpoint, ReCell is going to dominate the market. From an acne scarring or vitiligo standpoint, I think it can capture significant market share."
This is an excerpt from the Streetwise Reports interview with Jason Napodano, "" To read his comments on other companies, visit .
Investors rely on to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. Our exclusive interviews with leading industry experts and analysts provide a clear picture of the causes of macro-economic shifts and the strategies that will help you capitalize on these developing trends. This valuable insight is integrated with in-depth company information, summaries from the latest research and news that will help you make smart investment decisions.
Streetwise Reports, LLC - The Life Sciences Report
Brandon Fung
Email:
Tel: 707-981-8107
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 05.08.2013 - 06:00 Uhr
Sprache: Deutsch
News-ID 1251604
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
SAN FRANCISCO, CA
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 177 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Avita Medical Ltd Expected to Dominate Market for Burns and Scalds Treatment, Says Zacks Analyst via Interview With The Life Sciences Report
"
steht unter der journalistisch-redaktionellen Verantwortung von
The Life Sciences Report (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
